Hologic, Inc. (NASDAQ:HOLX) Shares Acquired by Stifel Financial Corp

Stifel Financial Corp increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 115.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,354 shares of the medical equipment provider’s stock after acquiring an additional 10,924 shares during the quarter. Stifel Financial Corp’s holdings in Hologic were worth $1,658,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of HOLX. Innealta Capital LLC acquired a new position in Hologic in the second quarter valued at $25,000. Wolff Wiese Magana LLC acquired a new position in Hologic in the 3rd quarter valued at about $25,000. Sunbelt Securities Inc. purchased a new stake in Hologic during the 2nd quarter valued at approximately $37,000. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the period. Finally, Cromwell Holdings LLC grew its stake in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX opened at $71.65 on Friday. Hologic, Inc. has a 12-month low of $70.36 and a 12-month high of $84.67. The stock has a market cap of $16.26 billion, a P/E ratio of 21.52, a PEG ratio of 2.38 and a beta of 0.96. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average of $78.65 and a two-hundred day moving average of $78.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 EPS. As a group, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on HOLX. Raymond James increased their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Royal Bank of Canada lifted their target price on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Mizuho reduced their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average price target of $89.50.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.